Corcept Therapeutics Incorporated (CORT - Free Report) was a big mover last session, as its shares rose over 8% on the day. The move came after the company delivered robust second-quarter 2017 results. This breaks the recent trend of the company, as the stock is now trading above the volatile price range of $11.90 to $12.97 in the past one-month time frame.
The company has seen one negative estimate revisions in the past 30 days while the Zacks Consensus Estimate hasn’t been in a trend /remained unchanged. The recent price action is encouraging though, so make sure to keep a close watch on this firm in the near future.
Corcept currently carries a Zacks Rank #3 (Hold).
A better-ranked stock worth considering in the Medical - Drugs space is Nivalis Therapeutics, Inc. (ALPN - Free Report) sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Is CORT going up? Or down? Predict to see what others think: Up or Down
More Stock News: Tech Opportunity Worth $386 Billion in 2017
From driverless cars to artificial intelligence, we've seen an unsurpassed growth of high-tech products in recent months. Yesterday's science-fiction is becoming today's reality. Despite all the innovation, there is a single component no tech company can survive without. Demand for this critical device will reach $387 billion this year alone, and it's likely to grow even faster in the future.
Zacks has released a brand-new Special Report to help you take advantage of this exciting investment opportunity. Most importantly, it reveals 4 stocks with massive profit potential.
See these stocks now>>